News

Phase 3 data shows bulevirtide benefit in hepatitis D
“For us in the hepatitis D field, it is a really exciting time; it’s completely novel data and game-changing for patients.”
“For us in the hepatitis D field, it is a really exciting time; it’s completely novel data and game-changing for patients.”
A pharmacist-led program seeks to improve the discharge process, decrease hospital readmissions, and reduce incidence of adverse events for...
The Veterans Health Administration has created a national multidisciplinary workgroup using a learning health system approach to identify gaps in...
This study compared the efficacy and safety of clinical pharmacy specialists’ management of tobacco cessation therapy using varenicline with that...
A chief resident and colleagues discuss the case of a previously active Air Force veteran with a history of substance use presenting with painful...
This cohort study assessed whether a risk assessment calculator for venous thromboembolism that was embedded in the admission order set would...
Background: Pancytopenia is a result of increased destruction or decreased production of bone marrow cells and has a broad...
As temperatures climb, we must redouble our efforts to educate patients about the dangers of extreme heat and advocate for federal policies and...